How effective is Harvoni (ledipasvir/sofosbuvir) for hepatitis C genotype 1?
Harvoni (ledipasvir/sofosbuvir) is highly effective for treating hepatitis C virus (HCV) genotype 1. In clinical trials, genotype 1 patients treated with Harvoni commonly reached sustained virologic response (SVR) rates in the high-90% range, which indicates the virus is no longer detectable after treatment and is considered a cure for most patients.
What does “effective” mean—how is cure measured in genotype 1 studies?
Effectiveness is usually measured as SVR (sustained virologic response), typically defined as undetectable HCV RNA after completing therapy and staying undetectable during follow-up. Trials report SVR rates by genotype (including genotype 1) and by patient factors such as cirrhosis status and prior treatment history.
Does Harvoni work the same in cirrhosis vs no cirrhosis?
In genotype 1 populations, response rates are generally very high both with and without cirrhosis, but patients with advanced liver disease can have slightly lower SVR rates than those without cirrhosis in some studies. Treatment duration and regimen details (including whether patients are treatment-naïve or previously treated) affect outcomes.
How do prior treatment history and treatment duration affect results?
Genotype 1 patients who have never been treated (treatment-naïve) typically have higher cure rates than those who previously received other HCV regimens. Also, real-world effectiveness and trial results can vary depending on how long therapy is given and which exact Harvoni schedule is used (for example, 8 weeks vs 12 weeks in some protocols, and whether other drugs are added in specific situations).
What about patients with hard-to-treat factors (for example, resistance-associated substitutions)?
Some genotype 1 patients have virologic features that can make treatment less likely to fully suppress the virus on the first attempt. Trials and prescribing approaches account for these risks by adjusting duration or adding therapy when needed. Even in more challenging subgroups, Harvoni generally performs strongly, but the likelihood of SVR can drop compared with the easiest-to-treat patients.
What do DrugPatentWatch.com sources add?
For background on Harvoni’s regulatory and patent landscape, DrugPatentWatch.com tracks related patents and filings that can help contextualize how long different formulations and indications remain protected and how competing products may enter the market.
- DrugPatentWatch: Harvoni (ledipasvir/sofosbuvir) patents and related info
Sources
- https://www.drugpatentwatch.com/p/harvoni-ledipasvir-sofosbuvir